263 related articles for article (PubMed ID: 27974822)
1. The double-domain cytidine deaminase APOBEC3G is a cellular site-specific RNA editing enzyme.
Sharma S; Patnaik SK; Taggart RT; Baysal BE
Sci Rep; 2016 Dec; 6():39100. PubMed ID: 27974822
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial hypoxic stress induces widespread RNA editing by APOBEC3G in natural killer cells.
Sharma S; Wang J; Alqassim E; Portwood S; Cortes Gomez E; Maguire O; Basse PH; Wang ES; Segal BH; Baysal BE
Genome Biol; 2019 Feb; 20(1):37. PubMed ID: 30791937
[TBL] [Abstract][Full Text] [Related]
3. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
5. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
6. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G.
Chen KM; Harjes E; Gross PJ; Fahmy A; Lu Y; Shindo K; Harris RS; Matsuo H
Nature; 2008 Mar; 452(7183):116-9. PubMed ID: 18288108
[TBL] [Abstract][Full Text] [Related]
7. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
[TBL] [Abstract][Full Text] [Related]
8. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
[TBL] [Abstract][Full Text] [Related]
9. Improvement of C-to-U RNA editing using an artificial MS2-APOBEC system.
Li J; Fan G; Sakari M; Tsukahara T
Biotechnol J; 2024 Jan; 19(1):e2300321. PubMed ID: 38010373
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA.
Maiti A; Myint W; Kanai T; Delviks-Frankenberry K; Sierra Rodriguez C; Pathak VK; Schiffer CA; Matsuo H
Nat Commun; 2018 Jun; 9(1):2460. PubMed ID: 29941968
[TBL] [Abstract][Full Text] [Related]
11. Complementary function of the two catalytic domains of APOBEC3G.
Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
[TBL] [Abstract][Full Text] [Related]
12. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent.
Browne EP; Allers C; Landau NR
Virology; 2009 May; 387(2):313-21. PubMed ID: 19304304
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus X protein is capable of down-regulating protein level of host antiviral protein APOBEC3G.
Chen R; Zhao X; Wang Y; Xie Y; Liu J
Sci Rep; 2017 Jan; 7():40783. PubMed ID: 28098260
[TBL] [Abstract][Full Text] [Related]
14. Stem-loop structure preference for site-specific RNA editing by APOBEC3A and APOBEC3G.
Sharma S; Baysal BE
PeerJ; 2017; 5():e4136. PubMed ID: 29230368
[TBL] [Abstract][Full Text] [Related]
15. The implications of APOBEC3-mediated C-to-U RNA editing for human disease.
Van Norden M; Falls Z; Mandloi S; Segal BH; Baysal BE; Samudrala R; Elkin PL
Commun Biol; 2024 May; 7(1):529. PubMed ID: 38704509
[TBL] [Abstract][Full Text] [Related]
16. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
17. Structure and real-time monitoring of the enzymatic reaction of APOBEC3G which is involved in anti-HIV activity.
Furukawa A; Nagata T; Matsugami A; Habu Y; Sugiyama R; Hayashi F; Kobayashi N; Yokoyama S; Takaku H; Katahira M
Nucleic Acids Symp Ser (Oxf); 2009; (53):87-8. PubMed ID: 19749273
[TBL] [Abstract][Full Text] [Related]
18. APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.
Covino DA; Purificato C; Catapano L; Galluzzo CM; Gauzzi MC; Vella S; Lefebvre E; Seyedkazemi S; Andreotti M; Fantuzzi L
Front Immunol; 2018; 9():1839. PubMed ID: 30135687
[TBL] [Abstract][Full Text] [Related]
19. N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.
Lei YC; Tian YJ; Ding HH; Wang BJ; Yang Y; Hao YH; Zhao XP; Lu MJ; Gong FL; Yang DL
World J Gastroenterol; 2006 Dec; 12(46):7488-96. PubMed ID: 17167839
[TBL] [Abstract][Full Text] [Related]
20. The C-terminal cytidine deaminase domain of APOBEC3G itself undergoes intersegmental transfer for a target search, as revealed by real-time NMR monitoring.
Kamba K; Nagata T; Katahira M
Phys Chem Chem Phys; 2018 Jan; 20(5):2976-2981. PubMed ID: 28905055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
